NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 123)
Posted On: 03/20/2024 5:25:50 PM
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Info on $6.5M Registered Direct Offering
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the company and warrants to purchase up to 1,542,112 shares of common stock; the stocks and warrants are offered at a combined price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant. Genprex will be receive approximately $6.5 million in gross proceeds from the offering, before standard fees and expenses are deducted. According to the announcement, the warrants have an exercise price of $4.09 per share and will be exercisable on the date of issuance; they will expire five years following the date of issuance. The company anticipates the agreement, which will be subject to typical closing conditions, will close approximately about March 21, 2024. The company anticipates using the funds from the offering for working capital and general corporate purposes.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the company and warrants to purchase up to 1,542,112 shares of common stock; the stocks and warrants are offered at a combined price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant. Genprex will be receive approximately $6.5 million in gross proceeds from the offering, before standard fees and expenses are deducted. According to the announcement, the warrants have an exercise price of $4.09 per share and will be exercisable on the date of issuance; they will expire five years following the date of issuance. The company anticipates the agreement, which will be subject to typical closing conditions, will close approximately about March 21, 2024. The company anticipates using the funds from the offering for working capital and general corporate purposes.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)